LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), announced the appointment of Mark Goldberg, M.D. to Senior Vice President of Product Development, a key leadership position focused on progressing the Company’s clinical-stage enzyme replacement therapy, SBC-102, towards regulatory approval and advancing the Company’s other rare disease programs. Dr. Goldberg joins Synageva from Genzyme Corporation, where he most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®.
